Company Filing History:

12 out of 3,840

Imperial Chemical Industries Limited

patents

3 out of 1,200

National Research Development Corporation

where one patent can have more than one assignee

Years Active: 1976-2002

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6436691 - Chemical compounds (2002-08-20),

2. 5985281 - Chemical compounds (1999-11-16),

3. 5395838 - 6-substituted quinazolines processing anti-tumor activity (1995-03-07),

4. 5254679 - Cephalosporin intermediates (1993-10-19),

5. 5252573 - Anti-tumor agents (1993-10-12),

6. 5089499 - Quinazoline derivatives possessing anti-tumor activity (1992-02-18),

7. 5049558 - Cephalosporin derivatives (1991-09-17),

8. 4568691 - Anti-inflammatory esters of (1986-02-04),

9. 4520027 - Anti-inflammatory esters of 4-(1-hydroxy-2-[(acylamino)alkylamino]ethyl) (1985-05-28),

10. 4338316 - 9-Aryloxy prostane derivatives (1982-07-06),

11. 4109015 - Prostane derivatives (1978-08-22),

12. 4096337 - Prostane derivatives (1978-06-20),

13. 4004021 - Cyclopentane derivatives (1977-01-18),

14. 3953502 - Cyclopentane derivatives (1976-04-27),

Title: The Innovative Mind of Peter R Marsham

Introduction: Peter R Marsham is a distinguished inventor based in Poynton, GB, holding an impressive total of 14 patents to his name. His work primarily focuses on the development of advanced therapeutic systems, particularly in the field of cancer treatment.

Latest Patents: Among his latest innovations are chemical compounds related to Antibody Directed Enzyme Prodrug Therapy (ADEPT) systems designed for use in cancer therapies. These systems utilize mutated carboxypeptidase B (CPB) enzymes to enable targeted conversion of prodrugs into effective antineoplastic drugs. The enzyme conjugates he's developed are designed to be substantially non-immunogenic in humans and comprise a targeting moiety, such as an antibody, that binds to tumor-associated antigens. This cutting-edge approach allows for a more precise treatment method, as the prodrug is not significantly metabolized by unmutated natural enzymes in the body. A favored enzyme mutant identified in his patents is human pancreatic CPB, which includes a Lys or Arg residue at position 253. Additionally, the patents disclose suitable mustard prodrugs for optimal efficacy.

Career Highlights: Peter's professional journey includes pivotal roles in influential companies such as Imperial Chemical Industries Limited and the National Research Development Corporation. His contributions have played a significant role in advancing biopharmaceutical innovation and therapeutic development.

Collaborations: Throughout his career, Peter has collaborated with notable colleagues, including Andrew John Barker and Leslie R Hughes. These partnerships have been integral in refining his ideas and bringing groundbreaking therapeutic solutions to fruition.

Conclusion: Peter R Marsham's ongoing contributions to the field of cancer treatment through innovative patented technologies reflect his dedication as an inventor. His work not only showcases the potential of targeted therapy but also highlights the importance of collaboration in fostering advancements within the scientific community. As he continues to push the boundaries of medical innovation, Peter remains a notable figure in the realm of patentable inventions.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.